Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

被引：0

作者：

Takeru Shiroiwa

Takashi Fukuda

Kojiro Shimozuma

Mitsuko Mouri

Yasuhiro Hagiwara

Takuya Kawahara

Shozo Ohsumi

Yasuo Hozumi

Yoshiaki Sagara

Yasuo Ohashi

Hirofumi Mukai

机构：

[1] Department of Health and Welfare Services,Department of Biomedical Sciences, College of Life Sciences

[2] National Institute of Public Health,Department of Biostatistics, School of Public Health

[3] Ritsumeikan University,Biostatistics Division, Clinical Research Support Center

[4] Kanagawa Academy of Science and Technology (KAST),Department of Breast and Endocrine Surgery

[5] The University of Tokyo,Department of Integrated Science and Engineering

[6] The University of Tokyo Hospital,undefined

[7] Department of Breast Oncology,undefined

[8] National Hospital Organization Shikoku Cancer Center,undefined

[9] University of Tsukuba Hospital,undefined

[10] Department of Breast Surgery,undefined

[11] Ibaraki Prefectural Central Hospital,undefined

[12] Breast Surgery Department,undefined

[13] Social Medical Corporation Hakuaikai Sagara Hospital,undefined

[14] Chuo University,undefined

[15] Division of Breast and Medical Oncology,undefined

[16] National Cancer Center Hospital East,undefined

来源：

BMC Cancer | / 17卷

关键词：

Cost-effectiveness analysis; Quality-adjusted life years; Breast neoplasms; Randomized controlled trial; S-1; Taxoids;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
Shiroiwa, Takeru
Fukuda, Takashi
Shimozuma, Kojiro
Mouri, Mitsuko
Hagiwara, Yasuhiro
Kawahara, Takuya
Ohsumi, Shozo
Hozumi, Yasuo
Sagara, Yoshiaki
Ohashi, Yasuo
Mukai, Hirofumi
BMC CANCER, 2017, 17
[2] COST-EFFECTIVENESS OF FIRST-LINE S-1 THERAPY FOR METASTATIC BREAST CANCER PATIENTS COMPARED WITH TAXANES: AN ANALYSIS BASED ON THE RANDOMIZED PHASE III SELECT BC TRIAL
Shiroiwa, T.
Fukuda, T.
Shimozuma, K.
Mouri, M.
Hagiwara, Y.
Kawahara, T.
Ohsumi, S.
Hozumi, Y.
Sagara, Y.
Ohashi, Y.
Mukai, H.
VALUE IN HEALTH, 2016, 19 (07) : A737 - A737
[3] Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer
Kawahara, Takuya
Shimozuma, Kojiro
Shiroiwa, Takeru
Hagiwara, Yasuhiro
Uemura, Yukari
Watanabe, Takanori
Taira, Naruto
Fukuda, Takashi
Ohashi, Yasuo
Mukai, Hirofumi
ONCOLOGY, 2018, 94 (02) : 107 - 115
[4] Biomarker analysis of S-1 in SELECT-BC: A randomized phase III study of taxane versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT-BC EURECA).
Hara, Fumikata
Mukai, Hirofumi
Ohsumi, Shozo
Yotsumoto, Daisuke
Takashima, Tsutomu
Hozumi, Yasuo
Watanabe, Takanori
Saito, Tsuyoshi
Watanabe, Ken-ichi
Tsurutani, Junji
Toyama, Tatsuya
Akabane, Hiromitsu
Nishimura, Reiki
Taira, Naruto
Uemura, Yukari
Ohashi, Yasuo
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] Randomized phase III trial of taxanes versus S-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC: CSPOR-MBC01)
Watanabe, Takanori
Shimozuma, Kojiro
Imi, Kentaro
Doihara, Hiroyoshi
Akabane, Hiromitsu
Ueo, Hiroaki
Ohno, Shinji
Kashiwaba, Masahiro
Fukuuchi, Atsushi
Watanabe, Kenichi
Tsuneizumi, Michiko
Isaka, Hirotsugu
Uemura, Yukari
Ohashi, Yasuo
Mukai, Hirofumi
CANCER RESEARCH, 2015, 75
[6] Randomized phase III study of taxane versus TS-1 as first-line treatment for metastatic breast cancer (SELECT BC).
Hara, Fumikata
Matsubara, Nobuaki
Saito, Tsuyoshi
Takano, Toshimi
Park, Youngjin
Toyama, Tatsuya
Hozumi, Yasuo
Tsurutani, Junji
Moth, Shigeru
Takashima, Tsutomu
Watanabe, Takanori
Sagara, Yoshiaki
Nishimura, Reiki
Ohashi, Yasuo
Mukai, Hirofumi
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase III studies (SELECT BC-CONFIRM and SELECT BC)
Nishimura, Reiki
Mukai, Hirofumi
Uemura, Yukari
Akabane, Hiromitsu
Park, Youngjin
Takahashi, Masato
Sagara, Yoshiaki
Takashima, Tsutomu
Fujisawa, Tomomi
Hozumi, Yasuo
Kawahara, Takuya
Watanabe, Takanori
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)-A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)-
Park, Y.
Akabane, H.
Watanabe, T.
Takahashi, M.
Sagara, Y.
Nishimura, R.
Tsurutani, J.
Takashima, T.
Fujisawa, T.
Hozumi, Y.
Uemura, Y.
Mukai, H.
CANCER RESEARCH, 2019, 79 (04)
[9] Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer
Giuliani, Jacopo
Mantoan, Beatrice
Bonetti, Andrea
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 194 - 198
[10] Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group
Kwakman, Johannes J. M.
van Werkhoven, Erik
Simkens, Lieke H. J.
van Rooijen, Johan M.
van de Wouw, Yes A. J.
ten Tije, Albert J.
Creemers, Geert-Jan M.
Hendriks, Mathijs P.
Los, Maartje
van Alphen, Robbert J.
Polee, Marco B.
Muller, Erik W.
van der Velden, Ankie M. T.
van Voorthuizen, Theo
Koopman, Miriam
Mol, Linda
Punt, Cornelis J. A.
CLINICAL COLORECTAL CANCER, 2019, 18 (02) : E229 - E230

← 1 2 3 4 5 →